Q-State Biosciences Announces Presentation at the Upcoming Antiepileptic Drug & Device Trials XVI Symposium

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Q-State Biosciences (“Q-State”),  a discovery technology and therapeutics company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system, today announced the company will present at the upcoming 2021 Antiepileptic Drug & Device Trials (AEDD) XVI Symposium to be held June 16-18.

The presentation, entitled, “Technology-derived Antisense Oligonucleotide Therapeutics for Severe Monogenic Epilepsies," will highlight the company’s platform validation for epilepsy therapeutic discovery and initial proof of concept data targeting UBE3A for Dup15qSyndrome.

Presentation details are as follows:

Session Title: Session  VIII: Drug Pipeline—Pre-Clinical

Session  Date and Time: June  18, 2021, 8:50 AM - 10:00 AM EST

‍

About Q-State Biosciences

Q-State Biosciences is a discovery technology and therapeutics company based in Cambridge, Massachusetts. We integrate advanced human neuronal models, proprietary determinative measurement engineering and powerful AI/machine learning to discover and develop novel therapeutics for epilepsy, pain, and other disorders of the CNS. For more information, please visit www.qstatebio.com.

‍

Contacts

Business Development
Chani Maher
chani.maher@qstatebio.com
+1 617-945-5433

Media
Carolyn Noyes
cnoyes@macbiocom.com
+1 781-235-3060

‍

‍

‍